One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
Joseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J Singerman,1 Richard Donkor,1 Margaret Fink,1 Rya...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-11-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/one-year-and-18-month-outcomes-in-namd-patient-eyes-switched-to-broluc-peer-reviewed-fulltext-article-OPTH |
| _version_ | 1797486283907399680 |
|---|---|
| author | Coney JM McCoy JE Buxy Sinha S Sonbolian N Zhou L Hull TP Lewis SA Miller DG Novak MA Pendergast SD Pham H Platt SM Rao LJ Schartman JP Singerman LJ Donkor R Fink M Zubricky R Karcher H |
| author_facet | Coney JM McCoy JE Buxy Sinha S Sonbolian N Zhou L Hull TP Lewis SA Miller DG Novak MA Pendergast SD Pham H Platt SM Rao LJ Schartman JP Singerman LJ Donkor R Fink M Zubricky R Karcher H |
| author_sort | Coney JM |
| collection | DOAJ |
| description | Joseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J Singerman,1 Richard Donkor,1 Margaret Fink,1 Ryan Zubricky,4 Helene Karcher2 1Retina Associates of Cleveland Inc, Beachwood, OH, USA; 2Novartis Pharma AG, Basel, Switzerland; 3KMK Consulting, Morristown, NJ, USA; 4Geisinger Eye Institute, Danville, PA, USACorrespondence: Joseph M Coney, Retina Associates of Cleveland Inc, 24075 Commerce Park, Beachwood, OH, 44122, USA, Tel +1 (216) 831-5700, Email jconey@retina-assoc.comObjective: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alternating with another anti-VEGF.Methods: The overall study population comprised eyes that were given ≥ 1 brolucizumab injection between 1 October 2019 and 30 November 2021. The brolucizumab-only (BRO) cohort consisted of prior anti-VEGF-treated eyes treated exclusively with ≥ 3 brolucizumab injections over ≥ 12 or ≥ 18 months; the alternating brolucizumab (ALT) cohort comprised prior anti-VEGF-treated eyes treated with ≥ 2 brolucizumab injections and ≥ 1 other anti-VEGF over ≥ 12 or ≥ 18 months.Results: A total of 482 eyes received ≥ 1 brolucizumab injection during the study period. Mean VA changes from baseline were − 1.1± 15.1 letters (BRO cohort; n = 174) and 1.3± 13.0 letters (ALT cohort; n = 47) at Month 12, and 0.0± 13.5 letters (BRO cohort; n = 95) and − 7.3± 17.2 letters (ALT cohort; n = 29) at Month 18. Mean changes in injection intervals were +26.9± 48.1 days (BRO cohort) and +11.1± 17.3 days (ALT cohort) at Month 12 and +36.3± 52.3 days (BRO cohort) and +14.0± 19.9 days (ALT cohort) at Month 18. Mean changes in CMT were − 35.2± 108.1 μm (BRO cohort) and − 31.5± 91.2 μm (ALT cohort) at Month 12 and − 38.9± 75.0 μm (BRO cohort) and − 9.0± 59.9 μm (ALT cohort) at Month 18. Intraocular inflammation-related adverse events were recorded in 22/482 (4.6%) eyes.Conclusion: Treatment with either brolucizumab alone or brolucizumab alternating with another anti-VEGF can preserve vision, reduce CMT, and extend anti-VEGF injection intervals in patients with nAMD.Keywords: alternating anti-VEGF treatments, brolucizumab, neovascular age-related macular degeneration, wet age-related macular degeneration, 12-month outcomes, 18-month outcomes |
| first_indexed | 2024-03-09T23:32:00Z |
| format | Article |
| id | doaj.art-440d656f71254c8195abbe116b5b23e7 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-03-09T23:32:00Z |
| publishDate | 2023-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-440d656f71254c8195abbe116b5b23e72023-11-23T17:07:55ZengDove Medical PressClinical Ophthalmology1177-54832023-11-01Volume 173601361188437One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsConey JMMcCoy JEBuxy Sinha SSonbolian NZhou LHull TPLewis SAMiller DGNovak MAPendergast SDPham HPlatt SMRao LJSchartman JPSingerman LJDonkor RFink MZubricky RKarcher HJoseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J Singerman,1 Richard Donkor,1 Margaret Fink,1 Ryan Zubricky,4 Helene Karcher2 1Retina Associates of Cleveland Inc, Beachwood, OH, USA; 2Novartis Pharma AG, Basel, Switzerland; 3KMK Consulting, Morristown, NJ, USA; 4Geisinger Eye Institute, Danville, PA, USACorrespondence: Joseph M Coney, Retina Associates of Cleveland Inc, 24075 Commerce Park, Beachwood, OH, 44122, USA, Tel +1 (216) 831-5700, Email jconey@retina-assoc.comObjective: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alternating with another anti-VEGF.Methods: The overall study population comprised eyes that were given ≥ 1 brolucizumab injection between 1 October 2019 and 30 November 2021. The brolucizumab-only (BRO) cohort consisted of prior anti-VEGF-treated eyes treated exclusively with ≥ 3 brolucizumab injections over ≥ 12 or ≥ 18 months; the alternating brolucizumab (ALT) cohort comprised prior anti-VEGF-treated eyes treated with ≥ 2 brolucizumab injections and ≥ 1 other anti-VEGF over ≥ 12 or ≥ 18 months.Results: A total of 482 eyes received ≥ 1 brolucizumab injection during the study period. Mean VA changes from baseline were − 1.1± 15.1 letters (BRO cohort; n = 174) and 1.3± 13.0 letters (ALT cohort; n = 47) at Month 12, and 0.0± 13.5 letters (BRO cohort; n = 95) and − 7.3± 17.2 letters (ALT cohort; n = 29) at Month 18. Mean changes in injection intervals were +26.9± 48.1 days (BRO cohort) and +11.1± 17.3 days (ALT cohort) at Month 12 and +36.3± 52.3 days (BRO cohort) and +14.0± 19.9 days (ALT cohort) at Month 18. Mean changes in CMT were − 35.2± 108.1 μm (BRO cohort) and − 31.5± 91.2 μm (ALT cohort) at Month 12 and − 38.9± 75.0 μm (BRO cohort) and − 9.0± 59.9 μm (ALT cohort) at Month 18. Intraocular inflammation-related adverse events were recorded in 22/482 (4.6%) eyes.Conclusion: Treatment with either brolucizumab alone or brolucizumab alternating with another anti-VEGF can preserve vision, reduce CMT, and extend anti-VEGF injection intervals in patients with nAMD.Keywords: alternating anti-VEGF treatments, brolucizumab, neovascular age-related macular degeneration, wet age-related macular degeneration, 12-month outcomes, 18-month outcomeshttps://www.dovepress.com/one-year-and-18-month-outcomes-in-namd-patient-eyes-switched-to-broluc-peer-reviewed-fulltext-article-OPTHalternating anti-vegf treatmentsbrolucizumabneovascular age-related macular degenerationwet age-related macular degeneration12-month outcomes18-month outcomes |
| spellingShingle | Coney JM McCoy JE Buxy Sinha S Sonbolian N Zhou L Hull TP Lewis SA Miller DG Novak MA Pendergast SD Pham H Platt SM Rao LJ Schartman JP Singerman LJ Donkor R Fink M Zubricky R Karcher H One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents Clinical Ophthalmology alternating anti-vegf treatments brolucizumab neovascular age-related macular degeneration wet age-related macular degeneration 12-month outcomes 18-month outcomes |
| title | One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents |
| title_full | One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents |
| title_fullStr | One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents |
| title_full_unstemmed | One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents |
| title_short | One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents |
| title_sort | one year and 18 month outcomes in namd patient eyes switched to brolucizumab alone versus to brolucizumab alternating with other anti vegf agents |
| topic | alternating anti-vegf treatments brolucizumab neovascular age-related macular degeneration wet age-related macular degeneration 12-month outcomes 18-month outcomes |
| url | https://www.dovepress.com/one-year-and-18-month-outcomes-in-namd-patient-eyes-switched-to-broluc-peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT coneyjm oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT mccoyje oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT buxysinhas oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT sonboliann oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT zhoul oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT hulltp oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT lewissa oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT millerdg oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT novakma oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT pendergastsd oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT phamh oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT plattsm oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT raolj oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT schartmanjp oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT singermanlj oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT donkorr oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT finkm oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT zubrickyr oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents AT karcherh oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents |